Intrommune Therapeutics Announces Crowdfunding Fin

New York, May 09, 2018 (GLOBE NEWSWIRE) --

Intrommune Therapeutics is pleased to announce the launch of a crowdfunding campaign on the Netcapital platform. This campaign supports the next steps of development for INT-301, an oral mucosal immunotherapy (OMIT) product for the long-term treatment of peanut allergy using a patent-protected daily use toothpaste. Over the past two years, Intrommune Therapeutics has locked down the OMIT intellectual property portfolio and laid the groundwork for a research program to support the development of INT-301.

For information on how to invest in the crowdfunding campaign, follow the link to campaign:  https://netcapital.com/companies/intrommune

CEO Michael Nelson stated, “It is important to the company that its product candidates truly meet the needs of people with food allergies. This financing campaign helps the company continue to prioritize these efforts. It is an unfortunate fact that there are no FDA approved treatments available for any food allergy. Every investment in Intrommune Therapeutics will help us reach our goal of bringing this life altering allergy immunotherapy closer to development while providing investors the opportunity to make substantial returns if our efforts are successful.”

Chief Science Officer Erick Berglund, PhD, adds, “With the proceeds of this campaign, the company plans to file for investigational new drug (IND) status for INT-301 with the US Food and Drug Administration to initiate clinical trials and plan for the future development of OMIT for food allergies.”

About Oral Mucosal Immunotherapy Oral mucosal immunotherapy (OMIT) uses a specially formulated toothpaste to stabilize and deliver allergenic proteins to immunologically active areas of the oral cavity with the greatest potential for allergy desensitization. Success with allergy immunotherapy hinges on consistent exposure of a patient’s immune system to gradually “desensitize” the patient to the specific allergy trigger over time. OMIT promises advantages over other approaches to allergy immunotherapy due to its targeted delivery, simplified administration, and support of reliable, long-term adherence.

About Intrommune Therapeutics Intrommune is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies. OMIT is a long-term, patient-friendly, disease-modifying solution for the 220 million people, including 9 million adults and 6 million children in the U.S., who suffer from life-altering food allergies. Intrommune’s lead product, INT-301, is expected to be a safe, effective and convenient therapy for patients who suffer from peanut allergy. There is no FDA-approved treatment for peanut allergy or any other food allergy.

For more information, please visit www.intrommune.com .

Contact: Michelle Mantia Outreach Manager Intrommune Therapeutics mmantia@intrommune.com